Eli Lilly and Company (2019)
GPTKB entity
Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:CEO |
gptkb:David_A._Ricks
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:foundedYear |
1876
|
| gptkbp:founder |
gptkb:Eli_Lilly
|
| gptkbp:headquartersLocation |
gptkb:Indianapolis,_Indiana,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Eli Lilly and Company (2019)
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:name |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:netIncome |
$8.3 billion (2019)
|
| gptkbp:notableProduct |
gptkb:Alimta
gptkb:Humalog gptkb:Prozac gptkb:Trulicity gptkb:Zyprexa gptkb:Cialis |
| gptkbp:numberOfEmployees |
approximately 34,000
|
| gptkbp:revenue |
$22.3 billion (2019)
|
| gptkbp:stockExchange |
gptkb:NYSE
|
| gptkbp:stockSymbol |
gptkb:LLY
|
| gptkbp:website |
https://www.lilly.com/
|
| gptkbp:bfsParent |
gptkb:Elanco_Animal_Health
|
| gptkbp:bfsLayer |
6
|